The laryngofissure approach for near-infrared photoimmunotherapy in laryngeal cancer: A novel larynx-preservation strategy.

Auris Nasus LarynxJul 17, 2026 (epub)
Case ReportOtolaryngology (ENT)Oncology (Medical)

Naoki Nishio, Mayu Shigeyama, Akihisa Wada et al.

✦ AI-curated · Sources linked

Case in brief

A 67-year-old male with laryngeal cancer presented with hoarseness and was staged as cT2N2bM0, Stage IVA. After two years of concurrent chemoradiotherapy, he experienced local recurrence in the subglottic and posterior laryngeal regions. The laryngofissure approach for near-infrared photoimmunotherapy (NIR-PIT) was employed, resulting in successful treatment and preservation of the larynx.

Diagnostic / clinical pearl

The laryngofissure approach for NIR-PIT allows for effective treatment of recurrent laryngeal cancer while preserving laryngeal function, particularly in challenging anatomical locations.

Source

PubMed · PMID 42469051

Published in Auris Nasus Larynx. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Otolaryngology (ENT)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.